-- 根據週二提交給香港交易所的文件，廣東投資（HKG:0270）公佈，2026年第一季歸屬於母公司股東的淨利潤年增10%，從去年同期的13億港元增至14.4億港元。 這家基礎設施公司的股價在周三下午的交易中上漲了1%。 持續經營業務的營收年增9.3%，從去年同期的46.2億港元增至50.5億港元，主要得益於水資源業務收入的成長。
Related Articles
Equities
RBC Upgrades Tamboran Resources to Outperform From Sector Perform, Raises Price Target to $55 From $38, Keeps Speculative Risk
Tamboran Resources (TBN) has an average rating of buy and mean price target of $57.40 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$TBN
Asia
Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.
$HKG:2607$SHA:601607
Mining & Metals
CGI Q2 Adjusted Net Earnings $483.4M, up 0.6% YoY
$GIB-A.TO